Alzheon posted positive results from the company’s Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders such as Alzheimer’s disease. 

Anavex Life Sciences Corp. (NASDAQ:AVXL) may have just emerged as a significant player in the Alzheimer’s drug market. The clinical-stage biotech company specializes in the development of treatments for currently incurable diseases. It has stumbled upon AVANEX 3-71 which is a drug candidate that may have significant potential for reduction of synaptic loss, amyloid, and […]